凝块波形分析的评估,以评估因子VIII度治疗的患者的高凝血能力
Takeshi Matsumoto1, Hideo Wada2, Katsuya Shiraki2
1Department of Transfusion Medicine and Cell Therapy, Mie University Hospital, Tsu 514-8507, Japan.
Journal of clinical medicine
|October 14, 2023
概括
凝块波形分析-血时间 (CWA-TT) 显示,在用FVIII度治疗的血友病患者中,高凝血能力不同于标准APTT测试. 这种测试有助于评估血栓激增,这对于管理血友病治疗风险至关重要.
科学领域:
- 血液学 血液学 血液学
- 凝血科学 凝血科学
- 血栓形成研究研究
背景情况:
- 重度血友病的预防性治疗通常涉及高剂量的第八因子 (FVIII) 缩物.
- 血栓形成的危险因素,即高凝血性,是接受FVIII治疗的血友病患者的一个担忧.
- 凝块波形分析-血时间 (CWA-TT) 使用少量的血来测量FVIII活性.
研究的目的:
- 在接受FVIII缩剂或埃米齐祖马布的血友病患者中评估凝血能力.
- 为了比较CWA-TT,CWA-APTT和染色体测定在评估凝血中的有效性.
- 调查与血友病治疗相关的潜在高凝血风险.
主要方法:
- 使用激活的部分血栓形成时间 (APTT),TT和通过CWA.通过小组织因子诱导的FIX激活试验 (sTF/FIXa) 评估凝血能力.
- 对用FVIII缩剂和埃米齐祖马布治疗的患者以及健康志愿者的血进行了评估.
- 在不同试验和患者群体中比较FVIII活动测量.
主要成果:
- 与CWA-APTT和染色体检测相比,CWA-TT显示出明显更高的FVIII活性.
- 与对照组相比,在接受FVIII治疗的血友病患者中,CWA-APTT表明凝血能力较低,而CWA-sTF/FIXa则没有.
- 在接受FVIII度治疗的血友病患者中,CWA-TT显示出高凝血能力,特别是在富血小板的血中.
结论:
- 在接受埃米齐祖马布治疗的患者中,CWA-TT可以检测血栓爆发和高凝血能力.
- 虽然APTT表明FVIII缩剂使用者的凝血率较低,但CWA-TT表明高凝血性.
- 建议使用多种测定方法,包括CWA-TT,用于对血友病患者的综合凝血评估.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
726
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
726
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:16Clot Retraction and Fibrinolysis
6.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.3K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
13
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
13
01:30Venous Thrombosis IV: Nursing Management
14
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
14